Atabak Mokari Biography and Net Worth

Mr. Mokari joined Corcept as Chief Financial Officer in March 2021. He brings to the company nearly 20 years of leadership experience in life sciences and healthcare finance. From 2018 to 2020, he was Chief Financial Officer at Bellicum Pharmaceuticals, Inc. He served in the same capacity from 2016 to 2018 at medical device manufacturer IRIDEX Corporation. Mr. Mokari was a director at Wells Fargo Securities LLC’s healthcare investment banking group from 2013 to 2016, at UBS’s healthcare investment banking group from 2009 to 2013 and at Credit Suisse’s healthcare investment banking group from 2005 to 2009. Prior to that, he was a member of the business development team at Forest Laboratories, a pharmaceutical company, and an analyst at the private equity firm Olympus Partners and the investment banking firm Bowles Hollowell Conner & Co. Mr. Mokari earned an MBA from The Tuck School of Business at Dartmouth and a B.S. in Chemistry and Biology from Duke University.

What is Atabak Mokari's net worth?: The estimated net worth of Atabak Mokari is at least $1.11 million as of June 1st, 2026. Mr. Mokari owns 15,257 shares of Corcept Therapeutics stock worth more than $1,108,421 as of June 4th. This net worth evaluation does not reflect any other assets that Mr. Mokari may own. Learn More about Atabak Mokari's net worth.
How do I contact Atabak Mokari?: The corporate mailing address for Mr. Mokari and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Atabak Mokari's contact information.
Has Atabak Mokari been buying or selling shares of Corcept Therapeutics?: Over the course of the past ninety days, Atabak Mokari has sold $2,800,000.00 in shares of Corcept Therapeutics stock. Most recently, Atabak Mokari sold 40,000 shares of the business's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $70.00, for a transaction totalling $2,800,000.00. Following the completion of the sale, the chief financial officer now directly owns 15,257 shares of the company's stock, valued at $1,067,990. Learn More on Atabak Mokari's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Atabak Mokari (CFO), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, Corcept Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $3,314,000.00. In the last year, insiders at the biotechnology company sold shares 50 times. They sold a total of 777,313 shares worth more than $53,387,058.01. The most recent insider tranaction occured on June, 1st when insider Sean Maduck sold 25,000 shares worth more than $1,755,250.00. Insiders at Corcept Therapeutics own 20.7% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 6/1/2026.

Atabak Mokari Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/1/2026	Sell	40,000	$70.00	$2,800,000.00	15,257

Atabak Mokari Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $74.29

$72.29

$73.74

50 Day Range

MA: $50.26

$33.82

$72.65

2 Week Range

Now: $74.29

$28.66

$91.00

Volume

55,903 shs

Average Volume

1,742,992 shs

Market Capitalization

$7.97 billion

P/E Ratio

211.69

Dividend Yield

N/A

Beta

0.5